# VITRAKVI
> **NDA210861** · New Drug Application · Sponsor: BAYER HLTHCARE · Approved 2018-11-26
## Drug
- **FDA Application Number:** NDA210861
- **Application type:** New Drug Application
- **Brand name:** VITRAKVI
- **Generic name:** LAROTRECTINIB
- **Active ingredients:** LAROTRECTINIB SULFATE
- **Dosage form:** CAPSULE
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** BAYER HLTHCARE
- **Manufacturer:** Loxo Oncology, Inc.
- **First approval:** 2018-11-26
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861)
---
*MORVS · CC0 1.0*